1 Ocak 2019 Dergi makalesi Açık Erişim

Nayman, Ayse Hande; Siginc, Halime; Zemheri, Ebru; Yencilek, Faruk; Yildirim, Asif; Telci, Dilek

JSON-LD (schema.org)

{
  "@context": "https://schema.org/", 
  "@id": 69817, 
  "@type": "ScholarlyArticle", 
  "creator": [
    {
      "@type": "Person", 
      "affiliation": "Yeditepe Univ, Fac Engn, Dept Genet & Bioengn, Kayisdagi Cad, TR-34755 Istanbul, Turkey", 
      "name": "Nayman, Ayse Hande"
    }, 
    {
      "@type": "Person", 
      "affiliation": "Yeditepe Univ, Fac Engn, Dept Genet & Bioengn, Kayisdagi Cad, TR-34755 Istanbul, Turkey", 
      "name": "Siginc, Halime"
    }, 
    {
      "@type": "Person", 
      "affiliation": "Umraniye Training & Res Hosp, Dept Pathol, Istanbul, Turkey", 
      "name": "Zemheri, Ebru"
    }, 
    {
      "@type": "Person", 
      "affiliation": "Yeditepe Univ, Fac Sch Med, Yeditepe Univ Hosp, Istanbul, Turkey", 
      "name": "Yencilek, Faruk"
    }, 
    {
      "@type": "Person", 
      "affiliation": "Medeniyet Univ, Fac Med, Dept Urol, Istanbul, Turkey", 
      "name": "Yildirim, Asif"
    }, 
    {
      "@type": "Person", 
      "affiliation": "Yeditepe Univ, Fac Engn, Dept Genet & Bioengn, Kayisdagi Cad, TR-34755 Istanbul, Turkey", 
      "name": "Telci, Dilek"
    }
  ], 
  "datePublished": "2019-01-01", 
  "description": "Renal cell carcinoma (RCC) is the predominant type of kidney cancer. Mammalian target of rapamycin (mTOR) inhibitor everolimus is currently used as a second-line therapy for sorafenib or sunitinib-refractory metastatic RCC patients. The clinical limitation confronted during everolimus therapy is the onset of drug resistance that decreases the efficacy of the drug. Elevated level of anti-apoptotic Bcl-2 protein is proposed to be an emerging feedback loop for the acquired drug-resistance in various cancer types. In this study, the Bcl-2 inhibitor ABT-737 was used in combination with everolimus to enhance its anti-tumor effectiveness in everolimus-resistant RCC cell lines. Everolimus and ABT-737 combination synergistically led to a decrease in the proliferation of primary site A-498 and metastatic site Caki-1 RCC cell lines, which was accompanied by a reduction in protein levels of cell cycle and mTOR pathway proteins. In both RCC cell lines, everolimus-ABT-737 combination not only induced apoptosis, caspase and PARP-1 cleavage but also a decrease in Bcl-2 protein levels in parallel with a concomitant increase in Bim and Noxa levels.", 
  "headline": "Dual-Inhibition of mTOR and Bcl-2 Enhances the Anti-tumor Effect of Everolimus against Renal Cell Carcinoma In Vitro and In Vivo", 
  "identifier": 69817, 
  "image": "https://aperta.ulakbim.gov.tr/static/img/logo/aperta_logo_with_icon.svg", 
  "license": "http://www.opendefinition.org/licenses/cc-by", 
  "name": "Dual-Inhibition of mTOR and Bcl-2 Enhances the Anti-tumor Effect of Everolimus against Renal Cell Carcinoma In Vitro and In Vivo", 
  "url": "https://aperta.ulakbim.gov.tr/record/69817"
}